Search

everythinglearnresearchcommunity

for

Search:↓

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The post and conversation are about a hair loss treatment regimen involving 30% minoxidil cream nightly, 5% minoxidil in the mornings, finasteride, weekly 1.5 derma pen, daily 0.5 microneedling for minoxidil absorption, daily multivitamin with biotin, low-level laser therapy every other day, daily scalp massages, Hims shampoo, and daily coffee rinses. The user hopes for hair regrowth and plans to update in one year.

A user discusses their experience with dissolving high concentrations of minoxidil in various ethanol/PG ratios and mentions difficulties with combining it with RU58841. They note that a 5% minoxidil solution remains stable, while higher concentrations tend to precipitate.

User seeks treatment to increase minoxidil efficacy. Suggestions include microneedling, oral minoxidil, and Tretinoin, with mixed experiences and side effects.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The user shared progress pictures showing hair thickening after 4 months of using minoxidil and microneedling, and has started taking finasteride. They are considering increasing minoxidil dosage if results are not satisfactory and are questioning whether their hair loss is genetic or self-induced from previous minoxidil use for beard growth.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

The conversation is about the effectiveness of hair loss treatments like finasteride, dutasteride, and minoxidil. Users agree these treatments help maintain hair but don't guarantee miraculous regrowth, emphasizing early intervention for best results.

The user is seeking advice on the best treatment for male pattern baldness, diffuse thinning, and retrograde alopecia, comparing the effectiveness of finasteride, RU58841, and dutasteride, and considering whether to add minoxidil or switch to dutasteride or combine treatments. They are currently on finasteride and are contemplating if adding RU58841 or switching to dutasteride is better, and also asking about the comparison between pyrilutamide and RU58841.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

A 25-year-old male with 10 years of hair loss is using minoxidil and considering adding finasteride or dutasteride, possibly with microneedling, to improve hair regrowth before a hair transplant. Community members suggest starting a DHT blocker immediately, considering oral minoxidil, and addressing low vitamin D and HDL levels.

The conversation humorously discusses hair loss treatments, including topical finasteride, oral dutasteride, topical minoxidil, RU58841, peppermint oil, and microneedling. It also mentions lifestyle changes like converting to Islam and avoiding smoking, drinking, and partying.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The user is frustrated with hair regrowth despite using finasteride, minoxidil, dutasteride, RU58841, ketoconazole shampoo, and dermastamping. Others suggest improvement, advise against overmedication, and recommend consulting a doctor or considering a simpler regimen or hair transplant.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

The user experienced significant hair thickening after nearly 5 months on 5 mg oral minoxidil and over 10 years on 1 mg finasteride, with no side effects. They are considering a hair transplant for the hairline but are pleased with the current results.

The user wants to mix 0.2 ml of RU58841 solution with 2 ml of Alfatradiol to use 10 mg of RU58841 daily due to concerns about side effects. They are asking if this combination would be effective for hair loss treatment.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

The conversation is about hair loss treatment using finasteride and minoxidil, with the original poster considering adjusting their dosage after experiencing side effects. Other users suggest trying different dosages or adding dutasteride, emphasizing consistency and consulting a specialist if side effects occur.

A user shared a 1.5-year hair loss treatment progress using 1mg Finasteride and 5% Minoxidil, planning to switch to oral Minoxidil and considering adding RU58841. They saw gradual improvement, suspecting Finasteride as the main contributor since they might not respond to topical Minoxidil.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.